石四药集团(02005.HK)：取得中吲哚布芬片(0.2g)药品生产注册批件

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has obtained the production registration approval for Indobufene Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Indobufene Tablets are primarily used for treating ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The tablets can also be used to prevent thrombosis during hemodialysis [1]